The effect of the third dose of the BNT162b2 vaccine on anti-SARS-CoV-2 spike antibody levels in healthcare workers with and without COVID-19 infection

References

• [cited 2021 Jun 10]. Available from: http://www.gov.pl/>web>szczepimysie
   Google Scholar
• Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19:409–424.
   PubMed Web of Science ®Google Scholar
• al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326:35–45.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–192.
   PubMed Web of Science ®Google Scholar
• Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385:e85.
   PubMed Web of Science ®Google Scholar
• Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months.N Engl J Med. 2021;385:e84.
   PubMed Web of Science ®Google Scholar
• Salvagno GL, Henry BM, Pighi L, et al. Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers. J Infect. 2021;83:e4–e5.
   PubMed Web of Science ®Google Scholar
• Israel A, Merzon E, Schäffer AA, et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort. medRxiv. 2021:2021.08.03.21261496. Available from: https://doi.org/10.1101/2021.08.03.21261496
   Google Scholar
• Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407–1416.
   PubMed Web of Science ®Google Scholar
• Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers.N Engl J Med. 2021;385:1474–1484.
   PubMed Web of Science ®Google Scholar
• Angel Y, Spitzer A, Henig O, et al. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. JAMA. 2021;325:2457–2465.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205–1211.
   PubMed Web of Science ®Google Scholar
• Pouwels KB, Pritchard E, Matthews PC, et al. Effect of delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021;27:2127–2135.
   PubMed Web of Science ®Google Scholar
• Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398:2093–2100.
   PubMed Web of Science ®Google Scholar
• Thompson MG, Burgess JL, Naleway AL, et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021;385:320–329.
   PubMed Web of Science ®Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397:881–891.
   PubMed Web of Science ®Google Scholar
• Gobbi F, Buonfrate D, Moro L, et al. Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection. Viruses. 2021;13:1–10.
   Web of Science ®Google Scholar
• Subbarao S, Warrener LA, Hoschler K, et al. Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. Eurosurveillance. 2021;26:1–6.
   Web of Science ®Google Scholar
• Zhong D, Xiao S, Debes AK, et al. Durability of antibody levels after vaccination with mRNA SARS-CoV-2 vaccine in individuals with or without prior infection. J Am Med Assoc. 2021;326:1–8.
   Web of Science ®Google Scholar
• Wolszczak-Biedrzycka B, Bieńkowska A, Zaborowska JE, et al. Anti-SARS-CoV-2S antibody levels in healthcare workers 10 months after the administration of two BNT162b2 vaccine doses in view of demographic characteristic and previous COVID-19 infection. Vaccines. 2022;10:1–10.
   Web of Science ®Google Scholar
• Campo F, Venuti A, Pimpinelli F, et al. Antibody persistence 6 months post-vaccination with BNT162b2 among health care workers. Vaccines. 2021;9:14–22.
   Web of Science ®Google Scholar
• Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med. 2021;384:2259–2261.
   PubMed Web of Science ®Google Scholar
• Wolszczak-Biedrzycka B, Bié Nkowska A, Dorf J, et al. Assessment of post-vaccination antibody response eight months after the administration of BNT1622b2 vaccine to healthcare workers with particular emphasis on the impact of previous COVID-19 infection. Vaccines. 2021;9:1508.
   Web of Science ®Google Scholar
• Smoot K, Yang J, Tacker DH, et al. Persistence and protective potential of SARS-CoV-2 antibody levels after COVID-19 vaccination in a West Virginia Nursing Home Cohort. JAMA Netw Open. 2022;5:e2231334.
   PubMed Web of Science ®Google Scholar
• Shekhar R, Garg I, Pal S, et al. COVID-19 vaccine booster: to boost or not to boost. Infect Dis Rep. 2021;13:924–929.
   PubMed Web of Science ®Google Scholar
• Gilboa M, Mandelboim M, Indenbaum V, et al. Early immunogenicity and safety of the third dose of BNT162b2 mRNA Covid-19 vaccine among adults older than 60 years; real world experience. J Infect Dis. 2021;5:1–10.
   Google Scholar
• Peled Y, Ram E, Lavee J, et al. Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience. J Heart Lung Transplant. 2021;5:9–18.
   Google Scholar
• Krammer F, Srivastava K, Alshammary H, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384:1372–1374.
   PubMed Web of Science ®Google Scholar
• Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258–2276.
   PubMed Web of Science ®Google Scholar
• Bernal JL, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv. 2021:2021.05.22.21257658. Available from: https://doi.org/10.1101/2021.05.22.21257658
   Google Scholar
• Falsey AR, Frenck RW, Walsh EE, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med. 2021;385:1627–1629.
   PubMed Web of Science ®Google Scholar
• Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385:1244–1246.
   PubMed Web of Science ®Google Scholar
• Peled Y, Ram E, Lavee J, et al. Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience. J Heart Lung Transplant. 2021;40:759–762.
   PubMedGoogle Scholar
• Kamar N, Abravanel F, Marion O, et al. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385:661–662.
   PubMed Web of Science ®Google Scholar
• Werbel WA, Boyarsky BJ, Ou MT, et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann Intern Med. 2021;174:1330–1332.
   PubMed Web of Science ®Google Scholar
• Bensouna I, Caudwell V, Kubab S, et al. SARS-CoV-2 antibody response after a third dose of the BNT162b2 vaccine in patients receiving maintenance hemodialysis or peritoneal dialysis. Am J Kidney Dis. 2021;10:1–11.
   Google Scholar
• Study to describe the safety, tolerability, immunogenicity, and efficacy of RNA vaccine candidates against COVID-19 in healthy individuals – Full text view – ClinicalTrials.gov [Internet]. [cited 2022 Jan 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT04368728
   Google Scholar
• Flaxman A, Marchevsky NG, Jenkin D, et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet. 2021;398:981–990.
   PubMed Web of Science ®Google Scholar
• Soytas RB, Cengiz M, Islamoglu MS, et al. Antibody responses to COVID-19 vaccines in older adults. J Med Virol. 2021;6:1–15.
   Google Scholar
• Keskin AU, Bolukcu S, Ciragil P, et al. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol. 2022;94:39–41.
   PubMed Web of Science ®Google Scholar
• Faustini SE, Shields AM, Banham G, et al. Cross reactivity of spike glycoprotein induced antibody against delta and omicron variants before and after third SARS-CoV-2 vaccine dose. medRxiv. 2022:2021.12.30.21268308. Available from: https://doi.org/10.1101/2021.12.30.21268308
   Google Scholar
• Higgins V, Fabros A, Kulasingam V. Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation. J Clin Microbiol. 2021;59:1–14.
   Web of Science ®Google Scholar